Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;79(13):1467-1475.
doi: 10.1007/s40265-019-01175-0.

Polatuzumab Vedotin: First Global Approval

Emma D Deeks  1
Affiliations
Review

Polatuzumab Vedotin: First Global Approval

Emma D Deeks. Drugs. 2019 Sep.

Erratum in

Abstract

Polatuzumab vedotin (polatuzumab vedotin-piiq; Polivy™) is an antibody-drug conjugate comprising a monoclonal antibody against CD79b (a B cell receptor component) covalently conjugated to the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE) via a cleavable linker. After binding to CD79b on the B-cell surface, polatuzumab vedotin is internalized and the linker is cleaved, releasing MMAE into the cell, where it inhibits division and induces apoptosis. Polatuzumab vedotin is being developed by Genentech (a subsidiary of Roche) for the treatment of haematological malignancies. In June 2019, the US FDA granted accelerated approval to polatuzumab vedotin, in combination with bendamustine plus rituximab, for the treatment of adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two prior therapies. Use of the compound in combination with bendamustine plus rituximab is also under regulatory review for relapsed/refractory DLBCL in the EU and is in ongoing phase 1b/2 development in this setting or relapsed/refractory follicular lymphoma (FL) in several countries. Various other polatuzumab vedotin combination therapy regimens are also in phase 1b/2 development for relapsed/refractory non-Hodgkin lymphoma (NHL) [including DLBCL and FL] or in phase 2 or 3 development for previously untreated DLBCL, while polatuzumab vedotin monotherapy has been in phase 1 development for relapsed/refractory B-cell NHL in Japan. This article summarizes the milestones in the development of polatuzumab vedotin leading to this first approval for its use in combination with bendamustine plus rituximab for relapsed/refractory DLBCL.

PubMed Disclaimer

Conflict of interest statement

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a salaried employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Figures

None
Key milestones in the development of polatuzumab vedotin in relapsed/refractory DLBCL, focussing on phase 1b/2 trials. DLBCL diffuse large B-cell lymphoma, PRIME PRIority MEdicines
See this image and copyright information in PMC

References

    1. ADC Review. What are antibody-drug conjugates (ADCs)? J Antibody Drug Conjugates. 2019. https://www.adcreview.com/the-review/antibody-drug-conjugates/what-are-a.... Accessed 28 Jun 2019.
    1. The Human Protein Atlas. CD79B. 2019. https://www.proteinatlas.org/ENSG00000007312-CD79B/pathology. Accessed 28 June 2019.
    1. Genentech Inc. Polivy™ (Polatuzumab vedotin-piiq) for injection, for intravenous use: US Prescribing Information. 2019. https://www.fda.gov. Accessed 28 June 2019.
    1. U.S. Food and Drug Administration. FDA approves polatuzumab vedotin-piiq for diffuse large B-cell lymphoma. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro.... Accessed 28 Jun 2019.
    1. Seattle Genetics Inc. Seattle Genetics announces antibody-drug conjugate agreement with Genentech [media release]. 22 Apr 2002. http://www.seattlegenetics.com.

LinkOut - more resources